PA5-28000

antibody from Invitrogen Antibodies

Targeting: CSF2RB betaGMR, CD131, IL3RB, IL5RB

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-28000

Provider

Invitrogen Antibodies

Product name

CSF2RB Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: K562.

Concentration

1 mg/mL

References

Submitted references

Discovery of a novel potentially transforming somatic mutation in CSF2RB gene in breast cancer.

Rashid M, Ali R, Almuzzaini B, Song H, AlHallaj A, Abdulkarim AA, Mohamed Baz O, Al Zahrani H, Mustafa Sabeena M, Alharbi W, Hussein M, Boudjelal M
Cancer medicine 2021 Nov;10(22):8138-8150

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot using CSF2RB Polyclonal Antibody (Product # PA5-28000). Sample (30 µg of whole cell lysate). Lane A: K562 . 5% SDS PAGE. CSF2RB Polyclonal Antibody (Product # PA5-28000) diluted at 1:1,000.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of CSF2RB was performed using 70% confluent log phase THP-1 cells treated with 10 ng of GM-CSF for 15 minutes. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with CSF2RB Rabbit Polyclonal Antibody (Product # PA5-28000) at 5 µg/mL in 0.1% BSA, incubated at 4 degree Celsius overnight and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membrane localization. Panel e shows untreated cells with less membrane signal. Panel f represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

2 FIGURE Characterization of KAIMRC1 cells on protein level. (A) Western blot analysis of the KAIMRC1 cell line in normal (+) and serum-starved conditions(-) against P- CSF2RB , CSF2RB , P-AKT1, AKT1, JAK2, P-JAK2, STAT3, P-STAT3, STAT5, mTOR, and P-mTOR. Ligand-independent activation of AKT/mTOR pathway, as well as the JAK2/STAT pathway, was observed. (B) Comparative Western blot analysis of KAIMRC1, MDA-MB-231, and MCF-7 cell lines against CSF2RB . (C) Schematic representation of proposed activation of the AKT/mTOR pathway and JAK2/STAT pathway that might result in cell cycle survival and proliferation

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 2 Characterization of KAIMRC1 cells on protein level. (A) Western blot analysis of the KAIMRC1 cell line in normal (+) and serum-starved conditions(-) against P- CSF2RB , CSF2RB , P-AKT1, AKT1, JAK2, P-JAK2, STAT3, P-STAT3, STAT5, mTOR, and P-mTOR. Ligand-independent activation of AKT/mTOR pathway, as well as the JAK2/STAT pathway, was observed. (B) Comparative Western blot analysis of KAIMRC1, MDA-MB-231, and MCF-7 cell lines against CSF2RB . (C) Schematic representation of proposed activation of the AKT/mTOR pathway and JAK2/STAT pathway that might result in cell cycle survival and proliferation